Electromed, Inc. (ELMD)
| Market Cap | 227.40M +12.1% |
| Revenue (ttm) | 73.78M +15.3% |
| Net Income | 11.30M +49.9% |
| EPS | 1.30 +52.9% |
| Shares Out | 8.29M |
| PE Ratio | 21.11 |
| Forward PE | 18.86 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 38,291 |
| Open | 27.48 |
| Previous Close | 27.40 |
| Day's Range | 27.48 - 27.48 |
| 52-Week Range | 23.01 - 47.40 |
| Beta | 0.40 |
| Analysts | Strong Buy |
| Price Target | 48.50 (+76.75%) |
| Est. Earnings | Nov 11, 2026 |
About ELMD
Electromed, Inc. develops, manufactures, markets, and sells airway clearance therapy and related products that apply high frequency chest wall oscillation (HFCWO) therapy in pulmonary care for patients in the United States and internationally. The company provides SmartVest airway clearance system for patients with compromised pulmonary functions, including bronchiectasis and cystic fibrosis, as well as neuromuscular conditions, such as cerebral palsy, muscular dystrophies, amyotrophic lateral sclerosis, and post-surgical complications; SmartVe... [Read more]
Financial Performance
In fiscal year 2026, Electromed's revenue was $73.78 million, an increase of 15.27% compared to the previous year's $64.00 million. Earnings were $11.30 million, an increase of 49.94%.
Financial StatementsAnalyst Summary
According to 2 analysts, the average rating for ELMD stock is "Strong Buy." The 12-month stock price target is $48.5, which is an increase of 76.75% from the latest price.
News
Electromed Transcript: LD Micro 20th Annual Main Event Conference
The presentation highlighted an underpenetrated U.S. bronchiectasis market, a direct-to-patient model with high-70s gross margins, and plans to expand sales, product sizing, and hospital reach. Management expects double-digit revenue growth and further operating leverage.
Electromed Proxy statement: Proxy filing
Electromed filed a proxy statement on September 29, 2026, providing details for shareholder voting and corporate governance matters.
Electromed Proxy statement: Proxy filing
Electromed filed a proxy statement on September 29, 2026, providing details for shareholder voting and corporate governance matters.
Electromed Transcript: H.C. Wainwright 28th Annual Global Investment Conference
A single-product med tech company with strong financials and no debt is leveraging new clinical guidelines, increased disease awareness, and a vertically integrated model to expand in a $3 billion US market. Clinical outcomes and high margins support ongoing growth and investment.
Electromed, Inc. to Participate in the H.C. Wainwright 28th Annual Global Investment Conference and LD Micro 20th Annual Main Event
NEW PRAGUE, Minn.--(BUSINESS WIRE)--Electromed, Inc. to Participate in the H.C. Wainwright 28th Annual Global Investment Conference and LD Micro 20th Annual Main Event.
Electromed price target raised to $47 from $36 at Lake Street
Lake Street raised the firm’s price target on Electromed (ELMD) to $47 from $36 and keeps a Buy rating on the shares. Electromed exceeded expectations in its 15th consecutive quarter…
Electromed Earnings Call Transcript: Q4 2026
Achieved record revenue and profit for both Q4 and FY 2026, driven by strong home care growth and operational leverage. Expanded sales force and payer coverage, launched new awareness campaigns, and maintained high gross margins. Projecting double-digit growth and continued investment in FY 2027.
Electromed Annual report: Q4 2026
Electromed has published its Q4 2026 annual report on August 25, 2026.
Electromed Earnings release: Q4 2026
Electromed released its Q4 2026 earnings on August 25, 2026, summarizing the period's financial results.
Electromed Slides: Q4 2026
Electromed has posted slides in relation to its Q4 2026 quarterly earnings report, which was published on August 25, 2026.
Electromed announces planned retirement of CEO
Electromed (ELMD) announced that Jim Cunniff expects to retire as President and Chief Executive Officer, on or about April 2, 2027. Upon his retirement, he will resign from the Company’s…
Electromed reports Q4 EPS 39c vs. 25c last year
Reports Q4 revenue $19.4M, consensus $19.3M. “Fiscal 2026 was another exceptional year for Electromed (ELMD), as the company generated record revenues and profits. The fourth fiscal quarter marked our...
Electromed Announces CEO's Planned Retirement
NEW PRAGUE, Minn.--(BUSINESS WIRE)--Electromed Announces CEO's Planned Retirement.
Electromed, Inc. Announces Record Fiscal 2026 Fourth Quarter and Full Year Financial Results
NEW PRAGUE, Minn.--(BUSINESS WIRE)--Electromed, Inc. Announces Record Fiscal 2026 Fourth Quarter and Full Year Financial Results.
Electromed, Inc. to Report Q4 Fiscal 2026 Financial Results on August 25, 2026
NEW PRAGUE, Minn.--(BUSINESS WIRE)--Electromed, Inc. to Report Q4 Fiscal 2026 Financial Results on August 25, 2026.
Electromed price target raised to $40 from $38 at B. Riley
B. Riley raised the firm’s price target on Electromed (ELMD) to $40 from $38 and keeps a Buy rating on the shares. Electromed delivered record Q3 results with 18.4% revenue…
Electromed reports Q3 EPS 35c vs. 21c last year
Reports Q3 revenue $18.6M, consensus $17.6M. “I’m happy to report that Electromed (ELMD) has delivered its 14th consecutive quarter of year-over-year revenue and profit growth. Electromed’s unique bus...
Electromed Earnings Call Transcript: Q3 2026
Q3 saw 18.4% revenue growth and 76% higher operating income, driven by strong home care and hospital segments, expanded sales force, and successful market education campaigns. Cash position remains robust, with continued double-digit growth expected.
Electromed Earnings release: Q3 2026
Electromed released its Q3 2026 earnings on May 12, 2026, summarizing the period's financial results.
Electromed Quarterly report: Q3 2026
Electromed has published its Q3 2026 quarterly earnings report on May 12, 2026.
Electromed Slides: Q3 2026
Electromed has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on May 12, 2026.
Electromed, Inc. Announces Record Financial Performance in Fiscal 2026 Third Quarter
NEW PRAGUE, Minn.--(BUSINESS WIRE)--Electromed, Inc. Announces Record Financial Performance in Fiscal 2026 Third Quarter.
Electromed, Inc. to Report Q3 Fiscal 2026 Financial Results on May 12, 2026
NEW PRAGUE, Minn.--(BUSINESS WIRE)--Electromed, Inc. to Report Q3 Fiscal 2026 Financial Results on May 12, 2026.
Electromed Transcript: The 38th Annual Roth Conference
A profitable, debt-free medical device company specializing in airway clearance for bronchiectasis leverages a differentiated, patient-friendly SmartVest technology and a high-touch sales model. With a $3 billion addressable market and strong cash flow, it invests in growth and shareholder returns.
Electromed Earnings Call Transcript: Q2 2026
Q2 saw record revenue and profit growth, led by strong home care and distributor channels, with gross margin rising to 78.4%. Strategic initiatives expanded market reach and payer coverage, while a $10 million stock repurchase program and no debt underscore financial strength.